The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide
Abstract
Like other GLP-1 receptor agonists used for treatment of type 2 diabetes, liraglutide delays gastric emptying. In this clinical absorption study, the primary objective was to investigate the effect of liraglutide (at steady state) on the rate and/or extent of gastrointestinal (GI) absorption of concomitantly orally taken drugs from three classes of the Biopharmaceutics Classification System (BCS). To provide a general prediction on liraglutide drug-drug absorption interaction, single-dose pharmacokinetics of drugs representing BCS classes II (low solubility-high permeability; atorvastatin 40 mg and griseofulvin 500 mg), III (high solubility-low permeability; lisinopril 20 mg), and IV (low solubility-low permeability; digoxin 1 mg) were studied in healthy subjects at steady state of liraglutide 1.8 mg, or placebo, in a two-period crossover design. With liraglutide, the oral drugs atorvastatin, lisinopril, and digoxin showed delayed tmax (by ≤2 h) and did not meet the criterion for bioequivalence for Cmax (reduced Cmax by 27-38%); griseofulvin had similar tmax and 37% increased Cmax. Although the prespecified bioequivalence criterion was not met by all drugs, the overall plasma exposure (AUC) of griseofulvin, atorvastatin, lisinopril, and digoxin only exhibited minor changes and was not considered to be of clinical relevance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PK data on ACEI and GLP1 agonist co-treatment showed different effects by different GLP1RAs (Table 3); Still, all changes were interpreted as minor and non-clinically significant [23, 24, 30, 32, 38].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [24]
In the citing paper
“Liraglutide was an exception as it also decreased the AUC [24].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [24]
In the citing paper
“The PK studies with lixisenatide [36], liraglutide [24] and semaglutide [16, 27] demonstrated reduced Cmax and delayed tmax of atorvastatin, but overall minor changes in the AUC were not considered to be of clinical importance (Table 3).”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [24]
Citations
Cites
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Self-citationWu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Self-citationDigoxin intoxication: the relationship of clinical presentation to serum digoxin concentration
Smith, T. W., & Haber, E. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106457 · Cited by 336
Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Diabetes Care · doi:10.2337/dc12-1609 · Cited by 335
Sjögren, E., Abrahamsson, B., Augustijns, P., Becker, D., Bolger, M. B., Brewster, M., Brouwers, J., Flanagan, T., Harwood, M., Heinen, C., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.010 · Cited by 279
Self-citationSchjoldager, B. T. G., Mortensen, P. E., Christiansen, J., �rskov, C., & Holst, J. J. (1989) · Digestive Diseases and Sciences · doi:10.1007/bf01540341 · Cited by 178
Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight
Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang‐Christensen, M., & Bjerre Knudsen, L. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01557.x · Cited by 155
Glucagon-like peptide-1 (7–36)-NH2: a physiological inhibitor of gastric acid secretion in man
O’Halloran, D., Nikou, G. C., Kreymann, B., Ghatei, M. A., & Bloom, S. R. (1990) · Journal of Endocrinology · doi:10.1677/joe.0.1260169 · Cited by 91
Flint, A., Kapitza, C., Hindsberger, C., & Zdravkovic, M. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0110-x · Cited by 91
Self-citationEffect of Exenatide on the Steady‐State Pharmacokinetics of Digoxin
Kothare, P. A., Soon, D. K. W., Linnebjerg, H., Park, S., Chan, C., Yeo, A., Lim, M., Mace, K. F., & Wise, S. D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005278806 · Cited by 69
Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men
Soon, D., Kothare, P. A., Linnebjerg, H., Park, S., Yuen, E., Mace, K. F., & Wise, S. D. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006291622 · Cited by 54
Chatterjee, D. J., Khutoryansky, N., Zdravkovic, M., Sprenger, C. R., & Litwin, J. S. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009339189 · Cited by 54
Self-citationComparative effectiveness of liraglutide in the treatment of type 2 diabetes
Fadini, G. P., & Rigato, M. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s37644 · Cited by 47
Gastric emptying: a comparison of three methods
Glerup, H., Bluhme, H., Villadsen, G. E., Rasmussen, K., Ejskjær, N., & Dahlerup, J. F. (2007) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520701370922 · Cited by 45
Amidon, K. S., Langguth, P., Lennernäs, H., Yu, L., & Amidon, G. L. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.109 · Cited by 44
Self-citationJacobsen, L. V., Vouis, J., Hindsberger, C., & Zdravkovic, M. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010389471 · Cited by 41
Self-citationExenatide effects on statin pharmacokinetics and lipid response
Kothare, P. A., Linnebjerg, H., Skrivanek, Z., Reddy, S., Mace, K., Pena, A., Han, J., Fineman, M., & Mitchell, M. (2007) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp45114 · Cited by 36
Kapitza, C., Zdravkovic, M., Hindsberger, C., & Flint, A. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0044-y · Cited by 36
Self-citationKothare, P. A., Seger, M. E., Northrup, J., Mace, K., Mitchell, M. I., & Linnebjerg, H. (2012) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-12-8 · Cited by 35
Jiang, J., Zhang, J., Jacobsen, L. V., & Hu, P. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010389468 · Cited by 32
Ahmed, I. S., Aboul-Einien, M. H., Ibrahim, O. M., & Farid, S. F. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.07.002 · Cited by 29
Serum biomarkers for heart failure
Jarolı́m, P. (2006) · Cardiovascular Pathology · doi:10.1016/j.carpath.2006.01.001 · Cited by 25
Linnebjerg, H., Kothare, P., Park, S., Mace, K., & Mitchell, M. (2009) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp47651 · Cited by 17
Cited by
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
“These effects were not considered to be clinically relevant [44, 53, 54] and dose adjustments for co-administered drugs are not required [18, 19].”
BackgroundAn updated review of pharmacokinetic drug interactions and pharmacogenetics of statins
Hirota, T., Fujita, Y., & Ieiri, I. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1801634 · Cited by 188
INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
Dedov, I. I., Shestakova, M. V., Mel'nichenko, G. A., Mazurina, N. V., Andreeva, E. N., Bondarenko, I. Z., Руслановна, Г. З., Dzgoeva, F. K., Елисеев, М. С., Ershova, E. V., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12714 · Cited by 203
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
“140,147,153,155,159 However, statins are known to exhibit high interindividual variability in terms of pharmacokinetics, and GLP-1 RA administration did not affect the lipid-lowering effect of statins in clinical studies, indicating minimal clinical significance.”
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024) · Drug Safety · doi:10.1007/s40264-023-01392-3 · Cited by 97
“Liraglutide was an exception as it also decreased the AUC [24].”
BackgroundInfluential
Metadata
- Authors
- Malm-Erjefält, M., Ekblom, M., Vouis, J., Zdravkovic, M., & Lennernäs, H.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- IQVIA (United States) (US)
- Uppsala University (SE)
- Corresponding author
- Malm-Erjefält, Monika
- ORCID
- Lennernäs, Hans
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-10-12
- Volume
- 12
- Issue
- 11
- Pages
- 4166-4173
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2403796176
- Cited by
- 36
- References
- 25
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 7 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 6 · 2018: 1 · 2017: 1 · 2015: 1
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- liraglutide, gastrointestinal drug absorption, drug-drug interactions, Biopharmaceutics Classification System, GLP-1 receptor agonists, gastric emptying, atorvastatin, griseofulvin, lisinopril, digoxin, bioequivalence, pharmacokinetics, type 2 diabetes
- MeSH terms
- Atorvastatin, Liraglutide, Administration, Oral, Adolescent, Adult, Antifungal Agents, Antihypertensive Agents, Biopharmaceutics, Cardiotonic Agents, Computer Simulation, Digoxin, Double-Blind Method, Drug Interactions, Female, Gastric Emptying, Griseofulvin, Humans, Hypoglycemic Agents, Male, Middle Aged, Therapeutic Equivalency, Tissue Distribution, Lisinopril, Cross-Over Studies, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Young Adult, Gastrointestinal Absorption
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.